Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / RIGHT 10/15/2029
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
17.7M
-
Shares change
-
-1.15M
-
Total reported value, excl. options
-
$7.16M
-
Value change
-
+$3.21M
-
Number of buys
-
13
-
Number of sells
-
-11
-
Price
-
$0.22
Significant Holders of Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) as of Q3 2025
36 filings reported holding DMAAR - Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 as of Q3 2025.
Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.7M shares
.
Largest 10 shareholders include Polar Asset Management Partners Inc. (1.9M shares), Hudson Bay Capital Management LP (1.8M shares), Harraden Circle Investments, LLC (1.5M shares), TORONTO DOMINION BANK (1M shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (984K shares), ARISTEIA CAPITAL, L.L.C. (882K shares), Linden Advisors LP (850K shares), MANGROVE PARTNERS IM, LLC (850K shares), Clear Street Group Inc. (659K shares), and GLAZER CAPITAL, LLC (588K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.